Experimental Treatments for Epidermolysis Bullosa
B-VEC (beremagene geperpavec) is an experimental topical gene therapy being developed to treat dystrophic epidermolysis bullosa. It is designed to deliver a healthy or working copy of the human COL7A1 gene directly to a patient’s skin cells. A Phase 3 trial is currently ongoing.
EB-101 is am investigational gene therapy being developed for the treatment of recessive dystrophic epidermolysis bullosa. EB-101 consists of a correct copy of the COL7A1 gene packaged into a retrovirus. A Phase 3 trial is currently enrolling.
FCX-007 is being developed to treat recessive dystrophic epidermolysis bullosa. It is a cell-based therapy that genetically modifies a patient’s own skin cells to produce healthy copies of type 7 collagen. It is currently being tested in an ongoing Phase 1/2 trial.